Bevacizumab: all 1,786 studies that test it

Page 10 of 18. Open to participants first (285), then studies with results posted, then the rest; newest registration first within each.

• Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer PatientsTerminatedNCT06332079Phase 2
• Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)SuspendedNCT06329570Phase 1/2
• First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC PatientsActive, not recruitingNCT06313970Phase 2
• Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver MetastasesActive, not recruitingNCT06311851Phase 1/2
• A Study to Compare the Pharmacokinetics and Safety of QL1101 and EU-Avastin® in Healthy VolunteersCompletedNCT06232902Phase 1
• First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive PatientsActive, not recruitingNCT06121401Phase 4
• A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 CirrhosisActive, not recruitingNCT06096779Phase 2
• A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TAREActive, not recruitingNCT06040099Phase 2
• A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular CarcinomaWithdrawnNCT06006286Phase 1/2
• Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal CancerActive, not recruitingNCT05999812Phase 2
• A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical CancerWithdrawnNCT05998941Phase 2
• Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal CancerActive, not recruitingNCT05969899Phase 2
• Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+TWithdrawnNCT05886257Phase 2
• A Comparative Pharmacokinetic Study to Evaluate Different Manufacturing Batches of BAT1706 InjectionCompletedNCT05865574Phase 1
• Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)Active, not recruitingNCT05797246Phase 2
• RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal CancerStatus unknownNCT05785325Phase 2
• Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary CancerActive, not recruitingNCT05775159Phase 2
• Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+TStatus unknownNCT05760599Phase 2
• Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC PatientsActive, not recruitingNCT05751187Phase 2
• A Dosing Study of Intravitreal Bevacizumab for Retinopathy of PrematurityCompletedNCT05712642Phase 3
• Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung AdenocarcinomaStatus unknownNCT05675033Phase 2
• Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous CarcinomaStatus unknownNCT05665023Phase 2
• FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal CancerActive, not recruitingNCT05627635Phase 1/2
• Associations Between the Oral and Intestinal Microbiome and Neovascular Age-related Macular DegenerationCompletedNCT05604989Phase 3
• CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal CancerActive, not recruitingNCT05585814Phase 2
• Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCCActive, not recruitingNCT05546879Phase 1
• Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/AmplificationWithdrawnNCT05510427Phase 1
• Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 MutationActive, not recruitingNCT05491811Phase 2
• Evaluating Novel Therapies in ctDNA Positive GI CancersActive, not recruitingNCT05482516Phase 3
• A Phase I Clinical Trial of Bevacizumab InjectionCompletedNCT05476341Phase 1
• Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal CancerActive, not recruitingNCT05445778Phase 3
• Golden Halo, Static Magnetic and Electric Field Device, in Recurrent GlioblastomaWithdrawnNCT05410301Not applicable
• Bevacizumab Plus Nab-paclitaxel and Platinum for Immunotherapy-treated Non-squamous Non-small Cell Lung CancerActive, not recruitingNCT05407155Not applicable
• Efficacy and Safety of T+A+RAD in HCCStatus unknownNCT05396937Phase 2
• Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBCStatus unknownNCT05386524Phase 2
• Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain MetastasesStatus unknownNCT05357417Phase 2
• Bevacizumab Biosimilar Plus FOLFOX4 in the Treatment of Recurrent HCC After Liver TransplantationStatus unknownNCT05355155Phase 2
• A Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Malignant Pleural EffusionStatus unknownNCT05330065Phase 1/2
• A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian CancerStatus unknownNCT05325229Phase 2
• A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung CancerCompletedNCT05318443Phase 3
• TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal CancerStatus unknownNCT05314101Phase 2
• Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian CancerStatus unknownNCT05310344Phase 2
• Comparison of Combined Intravitreal Bevacizumab and Oral Acetazolamide Versus Intravitreal Bevacizumab Alone for the Treatment of Macular Edema Secondary to Retinal Vein OcclusionsStatus unknownNCT05290948Phase 2
• Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study)Status unknownNCT05277675Not applicable
• Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung CancerStatus unknownNCT05273814Phase 1
• Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R MutationCompletedNCT05263947Phase 2
• Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic CholangiocarcinomaStatus unknownNCT05251662Phase 2
• A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical CancerStatus unknownNCT05247619Phase 2
• Study of INCB123667 in Subjects With Advanced Solid TumorsActive, not recruitingNCT05238922Phase 1
• SMMART Adaptive Clinical Treatment (ACT) TrialWithdrawnNCT05238831Early Phase 1
• A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver CancerActive, not recruitingNCT05211323Phase 2
• A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian CancerTerminatedNCT05200364Phase 1
• GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) PatientsActive, not recruitingNCT05191784Phase 2
• A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain MetastasisWithdrawnNCT05180422Phase 1/2
• Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard TherapyTerminatedNCT05180006Phase 2
• A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical CancerTerminatedNCT05179239Phase 3
• A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian CancerStatus unknownNCT05170594Phase 2
• To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLCCompletedNCT05169801Phase 3
• Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian CancerStatus unknownNCT05158062Phase 2
• A Study on the Treatment Strategy of NVG Secondary to PDRCompletedNCT05156021Not applicable
• A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-CancerStatus unknownNCT05132413Phase 3
• An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)Active, not recruitingNCT05112965Phase 3
• A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal DisordersActive, not recruitingNCT05112861Phase 3
• Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male SubjectsCompletedNCT05110118Phase 1
• Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular CarcinomaWithdrawnNCT05109052Phase 1/2
• Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung CancerStatus unknownNCT05104281Phase 3
• Phase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma.Active, not recruitingNCT05097911Phase 1
• SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular CarcinomaTerminatedNCT05093608Phase 1
• Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid TumorsActive, not recruitingNCT05075993Phase 1
• CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal CancerWithdrawnNCT05070104Phase 1
• Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck CancersActive, not recruitingNCT05063552Phase 2/3
• Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract CancerCompletedNCT05052099Phase 1/2
• Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian CancerCompletedNCT05044871Phase 2
• Ranibizumab Vs Bevacizumab for Type 1 Retinopathy of PrematurityStatus unknownNCT05033106Phase 3
• HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCCStatus unknownNCT05029973Phase 2
• Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV BevacizumabActive, not recruitingNCT05029882Phase 1
• Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLCCompletedNCT04997382Phase 2
• Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular EdemaTerminatedNCT04991350Phase 4
• Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal CancerStatus unknownNCT04988191Phase 1/2
• Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical CancerStatus unknownNCT04973904Phase 2
• Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLCActive, not recruitingNCT04958811Phase 2
• Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 PatientsTerminatedNCT04954014Phase 2
• Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM)TerminatedNCT04952571Phase 2
• Combination Therapy of HAIC and HLX10 and HLX04 in HCC With Major Portal Vein Tumor ThrombosisStatus unknownNCT04947826Phase 2
• Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal MetastasisStatus unknownNCT04944069Not applicable
• Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM PatientsActive, not recruitingNCT04940546Phase 1/2
• Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian CancerActive, not recruitingNCT04938583Phase 1/2
• A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsActive, not recruitingNCT04931342Phase 2
• SBRT + Atezolizumab + Bevacizumab in Resectable HCCActive, not recruitingNCT04857684Early Phase 1
• A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRCTerminatedNCT04856787Phase 2/3
• Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCCStatus unknownNCT04843943Phase 1/2
• Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung CancerActive, not recruitingNCT04837716Phase 1
• Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaBActive, not recruitingNCT04776655Phase 3
• Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal CancerCompletedNCT04761614Phase 1
• 131I-Omburtamab, in Recurrent Medulloblastoma and EpendymomaActive, not recruitingNCT04743661Phase 2
• Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT04741165Phase 2
• A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMDCompletedNCT04740671Phase 3
• Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)CompletedNCT04739202Phase 2
• A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast CancerCompletedNCT04732598Phase 3
• Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung CancerCompletedNCT04730999Phase 2

← Bevacizumab overview